Apixaban
6 NDCs across 1 manufacturer|0 Generic,6 Brand
Apixaban is used to treat pulmonary embolism and venous thrombosis, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Dec 28, 2012, and the first generic was approved Dec 23, 2019. FDA's Orange Book lists 6 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $20.8 billion on Apixaban across 24.1 million claims for 4.4 million beneficiaries.
Apixaban is available as 6 NDCs from 1 manufacturer (0 generic, 6 brand), with NADAC prices from $5.51 to $5.52 per EA — a 0% difference between cheapest and most expensive. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
6
0G / 6B
Manufacturers
1
competing in market
Price Spread
$5.51 – $5.52
per EA
7d Activity
avg -0.0% WoW · of 6 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
E.R. Squibb & Sons, L.L.C. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Factor Xa Inhibitor class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
1 manufacturer producing APIXABAN
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
ELIQUIS 5 MG TABLET | $5.5211 per EA | 0.00% |
ELIQUIS 5 MG TABLET | $5.5211 per EA | 0.00% |
ELIQUIS 5 MG TABLET | $5.5211 per EA | 0.00% |
ELIQUIS 2.5 MG TABLET | $5.5128 per EA | -0.10% |
ELIQUIS 2.5 MG TABLET | $5.5128 per EA | -0.10% |
ELIQUIS DVT-PE TREATMENT 30-DAY STARTER 5 MG PACK | $5.5077 per EA | +0.03% |
Frequently Asked Questions
What is Apixaban used to treat?
Apixaban is used to treat pulmonary embolism and venous thrombosis, per the National Library of Medicine's MED-RT classification.
When did Apixaban become available as a generic?
FDA approved the first generic Apixaban (ANDA) on Dec 23, 2019. The Orange Book currently lists 6 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Apixaban?
In 2024, Medicare Part D spent $20.8 billion on Apixaban across 24.1 million claims for 4.4 million beneficiaries.
How many Apixaban products are on the market?
The Apixaban drug market contains 6 NDCs from 1 manufacturer — 0 generic and 6 brand products.
What is the price range for Apixaban?
NADAC reference prices for Apixaban range from $5.5077 to $5.5211 per EA — a 0% difference between cheapest and most expensive.
Which manufacturers make Apixaban?
1 manufacturer lists Apixaban in NADAC. Ranked by number of NDCs, the largest are E.R. Squibb & Sons, L.L.C. (6).
How has the price of Apixaban changed recently?
Over the past 7 days, 1 Apixaban NDC rose and 2 fell, with a market-wide average change of -0.0%.